In contrast, in the recent CANTOS trial an anti-IL-1β monoclonal antibody (canakinumab) reduced HF-related hospitalizations and mortality in patients with previous myocardial infarction (21), but the system-wide effects and mechanisms of action remain undefined. This evidence concerns the gene IL1B and hydrops fetalis.